Latest Breaking News On - Atossa therapeutics inc - Page 1 : vimarsana.com

Atossa Therapeutics Announces Support of Clinical Study Testing New, Artificial Intelligence, Breast Cancer Risk Assessment Model

SEATTLE, May 28, 2024 Atossa Therapeutics, Inc. , today announced support for a new Phase 2 study designed to validate an innovative, artificial intelligence driven, breast cancer risk.

Atossa Therapeutics to support AI-based breast cancer risk study

Atossa Therapeutics (NASDAQ:ATOS) Shares Pass Above Two Hundred Day Moving Average of $1.13

Atossa Therapeutics, Inc. (NASDAQ:ATOS – Get Free Report)’s stock price crossed above its 200-day moving average during trading on Thursday . The stock has a 200-day moving average of $1.13 and traded as high as $1.55. Atossa Therapeutics shares last traded at $1.46, with a volume of 1,163,998 shares traded. Wall Street Analysts Forecast Growth […]

Cantor Fitzgerald Reiterates Overweight Rating for Atossa Therapeutics (NASDAQ:ATOS)

Cantor Fitzgerald reissued their overweight rating on shares of Atossa Therapeutics (NASDAQ:ATOS – Free Report) in a research note published on Tuesday morning, Benzinga reports. A number of other brokerages have also weighed in on ATOS. HC Wainwright lifted their price target on shares of Atossa Therapeutics from $4.00 to $6.00 and gave the company […]

StockNews.com Upgrades Atossa Therapeutics (NASDAQ:ATOS) to Hold

StockNews.com upgraded shares of Atossa Therapeutics (NASDAQ:ATOS – Free Report) from a sell rating to a hold rating in a research note published on Tuesday. A number of other research analysts have also recently commented on ATOS. HC Wainwright boosted their target price on shares of Atossa Therapeutics from $4.00 to $6.00 and gave the […]

HC Wainwright Raises Atossa Therapeutics (NASDAQ:ATOS) Price Target to $6.00

Atossa Therapeutics (NASDAQ:ATOS – Free Report) had its target price upped by HC Wainwright from $4.00 to $6.00 in a research report released on Monday morning, Benzinga reports. HC Wainwright currently has a buy rating on the stock. HC Wainwright also issued estimates for Atossa Therapeutics’ Q2 2024 earnings at ($0.05) EPS, Q3 2024 earnings […]

Atossa Therapeutics (NASDAQ:ATOS) Releases Quarterly Earnings Results, Beats Expectations By $0.02 EPS

Atossa Therapeutics (NASDAQ:ATOS – Get Free Report) posted its earnings results on Monday. The company reported ($0.05) EPS for the quarter, beating analysts’ consensus estimates of ($0.07) by $0.02, Zacks reports. Atossa Therapeutics Trading Up 4.5 % NASDAQ:ATOS opened at $1.61 on Thursday. The stock has a 50 day moving average of $1.59 and a […]

Atossa Therapeutics (NASDAQ:ATOS) Releases Earnings Results

Atossa Therapeutics (NASDAQ:ATOS – Get Free Report) issued its earnings results on Monday. The company reported ($0.05) earnings per share for the quarter, topping the consensus estimate of ($0.07) by $0.02, Zacks reports. Atossa Therapeutics Price Performance Shares of ATOS opened at $1.61 on Thursday. Atossa Therapeutics has a 12-month low of $0.62 and a […]

Atossa Therapeutics Announces Last Patient, Last Dose in its Phase 2 Karisma-Endoxifen Clinical Trial

Atossa Therapeutics (NASDAQ:ATOS) Releases Earnings Results, Beats Estimates By $0.02 EPS